Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study.
Identifieur interne : 001302 ( PubMed/Curation ); précédent : 001301; suivant : 001303Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study.
Auteurs : Lionel Piroth [France] ; Odile Launay [France] ; Marie-Louise Michel [France] ; Abderrahmane Bourredjem ; Patrick Miailhes ; Faiza Ajana ; Catherine Chirouze [France] ; David Zucman ; Marie-Josee Wendling [France] ; Dani Nazzal [France] ; Fabrice Carrat [France] ; David Rey [France] ; Christine BinquetSource :
- The Journal of infectious diseases [ 1537-6613 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps de l'hépatite B (immunologie), Anticorps de l'hépatite B (isolement et purification), Antigènes de la nucléocapside du virus de l'hépatite virale B (immunologie), Femelle, Humains, Hépatite B (), Immunogénicité des vaccins, Infections à VIH (), Infections à VIH (immunologie), Infections à VIH (traitement médicamenteux), Mâle, Thérapie antirétrovirale hautement active, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Vaccins anti-hépatite B (administration et posologie), Vaccins anti-hépatite B (immunologie), Vaccins synthétiques (administration et posologie), Vaccins synthétiques (immunologie), Études prospectives.
- MESH :
- administration et posologie : Vaccins anti-hépatite B, Vaccins synthétiques.
- immunologie : Anticorps de l'hépatite B, Antigènes de la nucléocapside du virus de l'hépatite virale B, Infections à VIH, Vaccins anti-hépatite B, Vaccins synthétiques.
- isolement et purification : Anticorps de l'hépatite B.
- traitement médicamenteux : Infections à VIH.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Hépatite B, Immunogénicité des vaccins, Infections à VIH, Mâle, Thérapie antirétrovirale hautement active, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Études prospectives.
English descriptors
- KwdEn :
- Adult, Antiretroviral Therapy, Highly Active, Female, HIV Infections (complications), HIV Infections (drug therapy), HIV Infections (immunology), HIV-1, Hepatitis B (prevention & control), Hepatitis B Antibodies (immunology), Hepatitis B Antibodies (isolation & purification), Hepatitis B Core Antigens (immunology), Hepatitis B Vaccines (administration & dosage), Hepatitis B Vaccines (immunology), Humans, Immunogenicity, Vaccine, Male, Middle Aged, Prospective Studies, Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology).
- MESH :
- chemical , administration & dosage : Hepatitis B Vaccines, Vaccines, Synthetic.
- chemical , immunology : Hepatitis B Antibodies, Hepatitis B Core Antigens, Hepatitis B Vaccines, Vaccines, Synthetic.
- complications : HIV Infections.
- drug therapy : HIV Infections.
- immunology : HIV Infections.
- chemical , isolation & purification : Hepatitis B Antibodies.
- prevention & control : Hepatitis B.
- Adult, Antiretroviral Therapy, Highly Active, Female, HIV-1, Humans, Immunogenicity, Vaccine, Male, Middle Aged, Prospective Studies.
Abstract
Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these patients are scarce.
DOI: 10.1093/infdis/jiw011
PubMed: 26768256
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001302
Links to Exploration step
pubmed:26768256Curation
No country items
Abderrahmane Bourredjem<affiliation><nlm:affiliation>INSERM, CIC 1432, Centre d'investigation clinique (Epidémiologie clinique/ essais cliniques), CHU de Dijon.</nlm:affiliation><wicri:noCountry code="subField">CHU de Dijon</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Département des Maladies Infectieuses, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, INSERM U1052.</nlm:affiliation><wicri:noCountry code="subField">INSERM U1052</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Service des Maladies Infectieuses, CHU de Tourcoing.</nlm:affiliation><wicri:noCountry code="subField">CHU de Tourcoing</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Service de Médecine Interne, Hôpital Foch,Suresnes.</nlm:affiliation><wicri:noCountry code="subField">Suresnes</wicri:noCountry></affiliation><affiliation><nlm:affiliation>INSERM, CIC 1432, Centre d'investigation clinique (Epidémiologie clinique/ essais cliniques), CHU de Dijon.</nlm:affiliation><wicri:noCountry code="subField">CHU de Dijon</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study.</title><author><name sortKey="Piroth, Lionel" sort="Piroth, Lionel" uniqKey="Piroth L" first="Lionel" last="Piroth">Lionel Piroth</name><affiliation wicri:level="4"><nlm:affiliation>Département d'infectiologie, CHU de Dijon, MERS UMR1347, Université de Bourgogne, Dijon Cedex.</nlm:affiliation><orgName type="university">Université de Bourgogne</orgName><country>France</country><placeName><settlement type="city">Dijon</settlement><region type="region" nuts="2">Région Bourgogne</region></placeName></affiliation></author><author><name sortKey="Launay, Odile" sort="Launay, Odile" uniqKey="Launay O" first="Odile" last="Launay">Odile Launay</name><affiliation wicri:level="4"><nlm:affiliation>Université Paris Descartes, Sorbonne Paris Cité; INSERM, CIC 1417 , F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin Pasteur.</nlm:affiliation><orgName type="university">Université Paris-Descartes</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Michel, Marie Louise" sort="Michel, Marie Louise" uniqKey="Michel M" first="Marie-Louise" last="Michel">Marie-Louise Michel</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de Pathogenèse des virus de l'hépatite B, Département de Virologie, Institut Pasteur, INSERM U994, Paris.</nlm:affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName><wicri:orgArea>Laboratoire de Pathogenèse des virus de l'hépatite B, Département de Virologie, Institut Pasteur, INSERM U994</wicri:orgArea></affiliation></author><author><name sortKey="Bourredjem, Abderrahmane" sort="Bourredjem, Abderrahmane" uniqKey="Bourredjem A" first="Abderrahmane" last="Bourredjem">Abderrahmane Bourredjem</name><affiliation><nlm:affiliation>INSERM, CIC 1432, Centre d'investigation clinique (Epidémiologie clinique/ essais cliniques), CHU de Dijon.</nlm:affiliation><wicri:noCountry code="subField">CHU de Dijon</wicri:noCountry></affiliation></author><author><name sortKey="Miailhes, Patrick" sort="Miailhes, Patrick" uniqKey="Miailhes P" first="Patrick" last="Miailhes">Patrick Miailhes</name><affiliation><nlm:affiliation>Département des Maladies Infectieuses, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, INSERM U1052.</nlm:affiliation><wicri:noCountry code="subField">INSERM U1052</wicri:noCountry></affiliation></author><author><name sortKey="Ajana, Faiza" sort="Ajana, Faiza" uniqKey="Ajana F" first="Faiza" last="Ajana">Faiza Ajana</name><affiliation><nlm:affiliation>Service des Maladies Infectieuses, CHU de Tourcoing.</nlm:affiliation><wicri:noCountry code="subField">CHU de Tourcoing</wicri:noCountry></affiliation></author><author><name sortKey="Chirouze, Catherine" sort="Chirouze, Catherine" uniqKey="Chirouze C" first="Catherine" last="Chirouze">Catherine Chirouze</name><affiliation wicri:level="4"><nlm:affiliation>Service des Maladies Infectieuses, CHU de Besançon, Université de Franche-Comté</nlm:affiliation><country>France</country><placeName><settlement type="city" wicri:auto="siege">Besançon</settlement><region type="region" nuts="2">Franche-Comté</region></placeName><orgName type="university">Université de Franche-Comté</orgName><orgName type="institution" wicri:auto="newGroup">Université de Bourgogne Franche-Comté</orgName></affiliation></author><author><name sortKey="Zucman, David" sort="Zucman, David" uniqKey="Zucman D" first="David" last="Zucman">David Zucman</name><affiliation><nlm:affiliation>Service de Médecine Interne, Hôpital Foch,Suresnes.</nlm:affiliation><wicri:noCountry code="subField">Suresnes</wicri:noCountry></affiliation></author><author><name sortKey="Wendling, Marie Josee" sort="Wendling, Marie Josee" uniqKey="Wendling M" first="Marie-Josee" last="Wendling">Marie-Josee Wendling</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de Virologie, Hôpitaux Universitaires, Strasbourg.</nlm:affiliation><country>France</country><placeName><settlement type="city">Strasbourg</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Alsace (région administrative)</region></placeName><wicri:orgArea>Laboratoire de Virologie, Hôpitaux Universitaires</wicri:orgArea></affiliation></author><author><name sortKey="Nazzal, Dani" sort="Nazzal, Dani" uniqKey="Nazzal D" first="Dani" last="Nazzal">Dani Nazzal</name><affiliation wicri:level="4"><nlm:affiliation>Université Paris Descartes, Sorbonne Paris Cité; INSERM, CIC 1417 , F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin Pasteur.</nlm:affiliation><orgName type="university">Université Paris-Descartes</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Carrat, Fabrice" sort="Carrat, Fabrice" uniqKey="Carrat F" first="Fabrice" last="Carrat">Fabrice Carrat</name><affiliation wicri:level="3"><nlm:affiliation>INSERM, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Sorbonne Universités, UPMC Univ Paris 06, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Public Health Unit, Saint-Antoine Hospital, AP-HP, Paris.</nlm:affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName><wicri:orgArea>INSERM, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Sorbonne Universités, UPMC Univ Paris 06, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Public Health Unit, Saint-Antoine Hospital, AP-HP</wicri:orgArea></affiliation></author><author><name sortKey="Rey, David" sort="Rey, David" uniqKey="Rey D" first="David" last="Rey">David Rey</name><affiliation wicri:level="1"><nlm:affiliation>Center for HIV infection care, Hôpitaux Universitaires, Strasbourg Cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Center for HIV infection care, Hôpitaux Universitaires, Strasbourg Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Binquet, Christine" sort="Binquet, Christine" uniqKey="Binquet C" first="Christine" last="Binquet">Christine Binquet</name><affiliation><nlm:affiliation>INSERM, CIC 1432, Centre d'investigation clinique (Epidémiologie clinique/ essais cliniques), CHU de Dijon.</nlm:affiliation><wicri:noCountry code="subField">CHU de Dijon</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26768256</idno><idno type="pmid">26768256</idno><idno type="doi">10.1093/infdis/jiw011</idno><idno type="wicri:Area/PubMed/Corpus">001302</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001302</idno><idno type="wicri:Area/PubMed/Curation">001302</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001302</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study.</title><author><name sortKey="Piroth, Lionel" sort="Piroth, Lionel" uniqKey="Piroth L" first="Lionel" last="Piroth">Lionel Piroth</name><affiliation wicri:level="4"><nlm:affiliation>Département d'infectiologie, CHU de Dijon, MERS UMR1347, Université de Bourgogne, Dijon Cedex.</nlm:affiliation><orgName type="university">Université de Bourgogne</orgName><country>France</country><placeName><settlement type="city">Dijon</settlement><region type="region" nuts="2">Région Bourgogne</region></placeName></affiliation></author><author><name sortKey="Launay, Odile" sort="Launay, Odile" uniqKey="Launay O" first="Odile" last="Launay">Odile Launay</name><affiliation wicri:level="4"><nlm:affiliation>Université Paris Descartes, Sorbonne Paris Cité; INSERM, CIC 1417 , F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin Pasteur.</nlm:affiliation><orgName type="university">Université Paris-Descartes</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Michel, Marie Louise" sort="Michel, Marie Louise" uniqKey="Michel M" first="Marie-Louise" last="Michel">Marie-Louise Michel</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de Pathogenèse des virus de l'hépatite B, Département de Virologie, Institut Pasteur, INSERM U994, Paris.</nlm:affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName><wicri:orgArea>Laboratoire de Pathogenèse des virus de l'hépatite B, Département de Virologie, Institut Pasteur, INSERM U994</wicri:orgArea></affiliation></author><author><name sortKey="Bourredjem, Abderrahmane" sort="Bourredjem, Abderrahmane" uniqKey="Bourredjem A" first="Abderrahmane" last="Bourredjem">Abderrahmane Bourredjem</name><affiliation><nlm:affiliation>INSERM, CIC 1432, Centre d'investigation clinique (Epidémiologie clinique/ essais cliniques), CHU de Dijon.</nlm:affiliation><wicri:noCountry code="subField">CHU de Dijon</wicri:noCountry></affiliation></author><author><name sortKey="Miailhes, Patrick" sort="Miailhes, Patrick" uniqKey="Miailhes P" first="Patrick" last="Miailhes">Patrick Miailhes</name><affiliation><nlm:affiliation>Département des Maladies Infectieuses, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, INSERM U1052.</nlm:affiliation><wicri:noCountry code="subField">INSERM U1052</wicri:noCountry></affiliation></author><author><name sortKey="Ajana, Faiza" sort="Ajana, Faiza" uniqKey="Ajana F" first="Faiza" last="Ajana">Faiza Ajana</name><affiliation><nlm:affiliation>Service des Maladies Infectieuses, CHU de Tourcoing.</nlm:affiliation><wicri:noCountry code="subField">CHU de Tourcoing</wicri:noCountry></affiliation></author><author><name sortKey="Chirouze, Catherine" sort="Chirouze, Catherine" uniqKey="Chirouze C" first="Catherine" last="Chirouze">Catherine Chirouze</name><affiliation wicri:level="4"><nlm:affiliation>Service des Maladies Infectieuses, CHU de Besançon, Université de Franche-Comté</nlm:affiliation><country>France</country><placeName><settlement type="city" wicri:auto="siege">Besançon</settlement><region type="region" nuts="2">Franche-Comté</region></placeName><orgName type="university">Université de Franche-Comté</orgName><orgName type="institution" wicri:auto="newGroup">Université de Bourgogne Franche-Comté</orgName></affiliation></author><author><name sortKey="Zucman, David" sort="Zucman, David" uniqKey="Zucman D" first="David" last="Zucman">David Zucman</name><affiliation><nlm:affiliation>Service de Médecine Interne, Hôpital Foch,Suresnes.</nlm:affiliation><wicri:noCountry code="subField">Suresnes</wicri:noCountry></affiliation></author><author><name sortKey="Wendling, Marie Josee" sort="Wendling, Marie Josee" uniqKey="Wendling M" first="Marie-Josee" last="Wendling">Marie-Josee Wendling</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de Virologie, Hôpitaux Universitaires, Strasbourg.</nlm:affiliation><country>France</country><placeName><settlement type="city">Strasbourg</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Alsace (région administrative)</region></placeName><wicri:orgArea>Laboratoire de Virologie, Hôpitaux Universitaires</wicri:orgArea></affiliation></author><author><name sortKey="Nazzal, Dani" sort="Nazzal, Dani" uniqKey="Nazzal D" first="Dani" last="Nazzal">Dani Nazzal</name><affiliation wicri:level="4"><nlm:affiliation>Université Paris Descartes, Sorbonne Paris Cité; INSERM, CIC 1417 , F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin Pasteur.</nlm:affiliation><orgName type="university">Université Paris-Descartes</orgName><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Carrat, Fabrice" sort="Carrat, Fabrice" uniqKey="Carrat F" first="Fabrice" last="Carrat">Fabrice Carrat</name><affiliation wicri:level="3"><nlm:affiliation>INSERM, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Sorbonne Universités, UPMC Univ Paris 06, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Public Health Unit, Saint-Antoine Hospital, AP-HP, Paris.</nlm:affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName><wicri:orgArea>INSERM, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Sorbonne Universités, UPMC Univ Paris 06, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Public Health Unit, Saint-Antoine Hospital, AP-HP</wicri:orgArea></affiliation></author><author><name sortKey="Rey, David" sort="Rey, David" uniqKey="Rey D" first="David" last="Rey">David Rey</name><affiliation wicri:level="1"><nlm:affiliation>Center for HIV infection care, Hôpitaux Universitaires, Strasbourg Cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Center for HIV infection care, Hôpitaux Universitaires, Strasbourg Cedex</wicri:regionArea></affiliation></author><author><name sortKey="Binquet, Christine" sort="Binquet, Christine" uniqKey="Binquet C" first="Christine" last="Binquet">Christine Binquet</name><affiliation><nlm:affiliation>INSERM, CIC 1432, Centre d'investigation clinique (Epidémiologie clinique/ essais cliniques), CHU de Dijon.</nlm:affiliation><wicri:noCountry code="subField">CHU de Dijon</wicri:noCountry></affiliation></author></analytic><series><title level="j">The Journal of infectious diseases</title><idno type="eISSN">1537-6613</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antiretroviral Therapy, Highly Active</term><term>Female</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (immunology)</term><term>HIV-1</term><term>Hepatitis B (prevention & control)</term><term>Hepatitis B Antibodies (immunology)</term><term>Hepatitis B Antibodies (isolation & purification)</term><term>Hepatitis B Core Antigens (immunology)</term><term>Hepatitis B Vaccines (administration & dosage)</term><term>Hepatitis B Vaccines (immunology)</term><term>Humans</term><term>Immunogenicity, Vaccine</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Vaccines, Synthetic (administration & dosage)</term><term>Vaccines, Synthetic (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps de l'hépatite B (immunologie)</term><term>Anticorps de l'hépatite B (isolement et purification)</term><term>Antigènes de la nucléocapside du virus de l'hépatite virale B (immunologie)</term><term>Femelle</term><term>Humains</term><term>Hépatite B ()</term><term>Immunogénicité des vaccins</term><term>Infections à VIH ()</term><term>Infections à VIH (immunologie)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Mâle</term><term>Thérapie antirétrovirale hautement active</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Vaccins anti-hépatite B (administration et posologie)</term><term>Vaccins anti-hépatite B (immunologie)</term><term>Vaccins synthétiques (administration et posologie)</term><term>Vaccins synthétiques (immunologie)</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Hepatitis B Vaccines</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Hepatitis B Antibodies</term><term>Hepatitis B Core Antigens</term><term>Hepatitis B Vaccines</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins anti-hépatite B</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps de l'hépatite B</term><term>Antigènes de la nucléocapside du virus de l'hépatite virale B</term><term>Infections à VIH</term><term>Vaccins anti-hépatite B</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Hepatitis B Antibodies</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Anticorps de l'hépatite B</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Hepatitis B</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Antiretroviral Therapy, Highly Active</term><term>Female</term><term>HIV-1</term><term>Humans</term><term>Immunogenicity, Vaccine</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Hépatite B</term><term>Immunogénicité des vaccins</term><term>Infections à VIH</term><term>Mâle</term><term>Thérapie antirétrovirale hautement active</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Études prospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these patients are scarce.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26768256</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2017</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>213</Volume><Issue>11</Issue><PubDate><Year>2016</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study.</ArticleTitle><Pagination><MedlinePgn>1735-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiw011</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these patients are scarce.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prospective multicenter study was conducted to assess the immunogenicity of HBV vaccination in 54 patients with an isolated anti-HBc profile and undetectable HIV load. They were vaccinated with 1 dose (20 µg) of recombinant HBV vaccine. Those with an anti-HBV surface antibody (anti-HBs) level of <10 mIU/mL 4 weeks after vaccination received 3 additional double doses (40 µg) at weeks 5, 9, and 24.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At week 4, 25 patients (46%) were responders. Only the ratio of CD4(+) T cells to CD8(+) T cells was associated with this response in multivariate analysis (odds ratio for +0.1, 1.32; 95% confidence interval, 1.07-1.63; P = .008). At week 28 and month 18, 58% of these patients (14 of 24) and 50% (10 of 20), respectively, maintained anti-HBs level of ≥10 mIU/mL.Among nonresponding patients at week 4, who received further vaccinations, 89% (24 of 27) and 81% (21 of 26) had an anti-HBs level of ≥10 mIU/mL at week 28 and month 18, respectively. The preS2-specific interferon γ T-cell response increased between week 0 and week 28 in patients who finally responded to reinforced vaccination (P = .03).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">All of the patients with an isolated anti-HBc profile who did not have an anti-HBs titer of >100 mIU/mL 4 weeks after a single recall dose of HBV vaccine should be further vaccinated with a reinforced triple double-dose scheme.</AbstractText><CopyrightInformation>© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Piroth</LastName><ForeName>Lionel</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Département d'infectiologie, CHU de Dijon, MERS UMR1347, Université de Bourgogne, Dijon Cedex.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launay</LastName><ForeName>Odile</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Université Paris Descartes, Sorbonne Paris Cité; INSERM, CIC 1417 , F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin Pasteur.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michel</LastName><ForeName>Marie-Louise</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Laboratoire de Pathogenèse des virus de l'hépatite B, Département de Virologie, Institut Pasteur, INSERM U994, Paris.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourredjem</LastName><ForeName>Abderrahmane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INSERM, CIC 1432, Centre d'investigation clinique (Epidémiologie clinique/ essais cliniques), CHU de Dijon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miailhes</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Département des Maladies Infectieuses, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, INSERM U1052.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ajana</LastName><ForeName>Faiza</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Service des Maladies Infectieuses, CHU de Tourcoing.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chirouze</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service des Maladies Infectieuses, CHU de Besançon, Université de Franche-Comté</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zucman</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Service de Médecine Interne, Hôpital Foch,Suresnes.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wendling</LastName><ForeName>Marie-Josee</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Laboratoire de Virologie, Hôpitaux Universitaires, Strasbourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nazzal</LastName><ForeName>Dani</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Université Paris Descartes, Sorbonne Paris Cité; INSERM, CIC 1417 , F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin Pasteur.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrat</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>INSERM, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Sorbonne Universités, UPMC Univ Paris 06, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Public Health Unit, Saint-Antoine Hospital, AP-HP, Paris.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rey</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for HIV infection care, Hôpitaux Universitaires, Strasbourg Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binquet</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM, CIC 1432, Centre d'investigation clinique (Epidémiologie clinique/ essais cliniques), CHU de Dijon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ANRS HB EP03 CISOVAC Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006510">Hepatitis B Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006512">Hepatitis B Core Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017325">Hepatitis B Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023241" MajorTopicYN="N">Antiretroviral Therapy, Highly Active</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006510" MajorTopicYN="N">Hepatitis B Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006512" MajorTopicYN="N">Hepatitis B Core Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017325" MajorTopicYN="N">Hepatitis B Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">HBV</Keyword><Keyword MajorTopicYN="Y">HIV</Keyword><Keyword MajorTopicYN="Y">immunology</Keyword><Keyword MajorTopicYN="Y">isolated anti-HBc</Keyword><Keyword MajorTopicYN="Y">vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26768256</ArticleId><ArticleId IdType="pii">jiw011</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiw011</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001302 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001302 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26768256
|texte= Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26768256" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |